Corporate Video

Enanta Pharmaceuticals is using its robust chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for viral infections and liver diseases. Enanta’s research and development efforts have produced clinical candidates for the following disease areas: respiratory syncytial virus (RSV), non-alcoholic steatohepatitis (NASH), hepatitis B virus (HBV), human metapneumovirus (hMPV) and SARS-CoV-2.

Enanta's research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is now sold by AbbVie, as part of its leading treatment for chronic HCV infection under the trade names MAVYRET™ (U.S) and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir).

Enanta’s wholly-owned pipeline includes EDP-938, an N-protein inhibitor for RSV; EDP-305, an FXR agonist for NASH/PBC; EDP-297, a follow-on FXR agonist for NASH; and EDP-514, a core inhibitor for HBV.

View our pipeline.

Enanta is headquartered in Watertown, Massachusetts.